<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01587144</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-LUC-11-01</org_study_id>
    <nct_id>NCT01587144</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)</brief_title>
  <official_title>An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the effectiveness of an investigational drug called&#xD;
      lucanthone, when combined with temozolomide (TMZ) and radiation in the treatment of&#xD;
      Glioblastoma Multiforme (GBM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an international, multicenter, randomized, double blind placebo controlled phase II&#xD;
      study to evaluate the safety and efficacy of lucanthone administered as an adjunct to&#xD;
      patients receiving primary treatment of GBM with temozolomide and radiation. Eligible&#xD;
      patients will be randomized to lucanthone or placebo arm in ratio of 1:1. The treatment&#xD;
      period will be in two phases ; an initial six weeks of concomitant therapy with temozolomide&#xD;
      and radiation, followed by a maintenance phase of six cycles of temozolomide given on Days 1&#xD;
      to 5 of a 28- day cycle (+/- 3 days). Lucanthone / placebo will be given as an add on in both&#xD;
      concomitant and maintenance phases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor's decision&#xD;
  </why_stopped>
  <start_date type="Actual">June 19, 2012</start_date>
  <completion_date type="Actual">April 15, 2013</completion_date>
  <primary_completion_date type="Actual">April 15, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>9 months</time_frame>
    <description>Progression Free Survival: defined as the time from randomization until objective tumor progression or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>one year</time_frame>
    <description>Fraction of patients with a Complete Response (CR) or Partial Response (PR) at anytime through the 12 months visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>one year</time_frame>
    <description>Overall Survival: The time from randomization until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profile of Lucanthone</measure>
    <time_frame>one year</time_frame>
    <description>Safety Profile of Lucanthone at 10-15 mg/kg/day.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a matching placebo as an adjunct in initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lucanthone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive Lucanthone as an adjunct in initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucanthone</intervention_name>
    <description>Lucanthone will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.</description>
    <arm_group_label>Lucanthone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide (TMZ)</intervention_name>
    <description>TMZ is administered at 75mg/m2 daily for 42 days during the concomitant phase. TMZ is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.&#xD;
Cycles 2-6: At the start of Cycle 2, the dose can be escalated to 200 mg/m2, if the common terminology criteria (CTC) nonhematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count (ANC) is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs.</description>
    <arm_group_label>Lucanthone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>60 Gy administered in 30 fractions for 42 days in the concomitant phase.</description>
    <arm_group_label>Lucanthone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. 18 and 70 years of age in India, 18 years and above in US&#xD;
&#xD;
          2. Histologically proven GBM who&#xD;
&#xD;
               -  May or may not have undergone surgery&#xD;
&#xD;
               -  Is scheduled to receive treatment with temozolomide and radiation.&#xD;
&#xD;
          3. Karnofsky score ≥ 70%.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of recurrent brain tumor.&#xD;
&#xD;
          2. Received temozolomide previously.&#xD;
&#xD;
          3. Absolute neutrophil count ≤ 1.5 X 109/L.&#xD;
&#xD;
          4. Screening platelet count &lt; 100 K/uL.&#xD;
&#xD;
          5. Screening bilirubin &gt; 1.6 mg/dL.&#xD;
&#xD;
          6. Screening creatinine &gt; 2.25 mg/dL in men and 1.8 mg/dL in women.&#xD;
&#xD;
          7. Screening ALT or AST &gt; 2.5 times the upper limit of the laboratory reference range.&#xD;
&#xD;
          8. Unstable medical condition or significant comorbid pathophysiology (e.g. active&#xD;
             infection, poorly controlled diabetes, unstable angina, severe heart failure) that&#xD;
             would interfere with his/her participation in the study.&#xD;
&#xD;
          9. Enrolled, or plans to enroll, in a concurrent treatment protocol with another&#xD;
             investigational product.&#xD;
&#xD;
         10. Receiving, or plans to receive, an anti-cancer therapy other than temozolomide during&#xD;
             the study.&#xD;
&#xD;
         11. Received prior chemotherapy or radiation therapy within four weeks of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dent Neurologic Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Hospital Moll Cancer Center/Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Hospital Hirsh Cancer Center/Cleveland Clinic</name>
      <address>
        <city>Mayfield</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gujarat Cancer Research Institute</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jaslok Hospital &amp; Research Centre</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400062</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhagwan Mahaveer Cancer Hospital &amp; Reseach Centre</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chittaranjan National Cancer Institute</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 11, 2012</study_first_submitted>
  <study_first_submitted_qc>April 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2012</study_first_posted>
  <disposition_first_submitted>September 30, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>October 8, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 13, 2021</disposition_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GBM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lucanthone</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

